Medigate - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 3,292,909 | 2,864,457 | 3,648,569 | 4,063,207 | 4,008,723 | 6,994,982 | 3,760,512 | 5,843,817 |
| Profit before tax | 355,387 | 367,051 | 911,441 | 1,254,115 | 977,689 | 2,193,413 | 368,453 | 1,590,574 |
| Net profit | - | - | - | - | 828,316 | 1,857,858 | 311,966 | 1,333,822 |
| Equity | 802,378 | 1,109,829 | 773,042 | 1,067,864 | 1,596,180 | 2,154,038 | 315,152 | 1,648,974 |
| Liabilities | - | - | - | - | 374,084 | 405,483 | 600,636 | 378,290 |
| Non-current assets | 87,448 | 126,052 | 73,232 | 91,957 | 49,773 | 29,158 | 23,393 | 18,353 |
| Current assets | 1,178,304 | 1,242,307 | 1,753,426 | 1,420,621 | 1,920,108 | 2,532,584 | 891,441 | 2,007,740 |
| Total assets | 1,265,752 | 1,368,359 | 1,826,658 | 1,512,578 | 1,969,881 | 2,561,742 | 914,834 | 2,026,093 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 1,484,535 | 947,171 | 901,320 |
| Social insurance contributions | - | - | - | - | - | 106,970 | 111,615 | 76,410 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +21.2% | -13.0% | +27.4% | +11.4% | -1.3% | +74.5% | -46.2% | +55.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | - | - | - | - | 42.0% | 72.5% | 34.1% | 65.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | 51.9% | 86.3% | 99.0% | 80.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | - | - | 20.7% | 26.6% | 8.3% | 22.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 10.8% | 12.8% | 25.0% | 30.9% | 24.4% | 31.4% | 9.8% | 27.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 0.2 | 0.2 | 1.9 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 372,784 | 343,736 | 405,397 | 439,266 | 391,095 | 631,128 | 320,044 | 899,049 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Medigate - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-01-16 | 2025-01-19 | 5134.43 |
| 2024-04-16 | 2024-04-21 | 11271.15 |
| 2022-08-23 | 2022-08-28 | 0.06 |
| 2022-07-25 | 2022-08-11 | 0.06 |
| 2022-05-17 | 2022-05-18 | 63.60 |
Medigate - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-02-21 | 2026-02-21 | 23408.44 |
| 2025-10-30 | 2025-11-02 | 13.46 |
| 2025-09-28 | 2025-10-25 | 3.4 |
| 2025-08-28 | 2025-09-03 | 5.58 |
| 2025-02-28 | 2025-03-06 | 12.36 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Medigate, UAB (code 302428935) is a private limited liability company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €5.84M and net profit of €1.33M, with a net profit margin of 22.8%. This marked a strong rebound from 2024, when revenue declined to €3.76M and net profit to €312.0K, after a larger 2023 base of €6.99M in revenue and €1.86M in net profit. Over the three-year period, profitability has remained positive, but results have moved notably with the sales cycle and cost structure. The latest year shows improved operating performance and higher earnings intensity compared with 2024. At the end of 2025, total assets stood at €2.03M, equity at €1.65M and liabilities at €378.3K, indicating a strong equity position and moderate leverage. Key ratios also point to efficient use of capital, with ROE at 80.9%, ROA at 65.8%, debt-to-equity at 0.23 and asset turnover at 2.88x. Revenue per employee was €974.0K, while profit per employee reached €222.3K.